Cargando…

P1541: PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.

Detalles Bibliográficos
Autores principales:	Serrano-Gonzalo, I., López de Frutos, L., Arévalo-Vargas, I., Fernández-Galán, M. Á., Morales-Conejo, M., Calle-Gordo, M. V., Vitoria-Miñana, I., Correcher-Medina, P., Madinaveitia-Ochoa, A., Hernández-Rivas, J. Á., García-Frade, J., Ibarretxe-Gerediaga, D., Delgado-Mateos, F., Tormo-Díaz, M. D. M., Ruíz-Guinaldo, M. Á., Mora-Casterá, E., Noya-Pereira, M. S., Albarracín-Arraigosa, A., López-Dupla, M., Balanzat-Muñoz, J., Lozano-Almela, M. L., Labbadia, F., Andrade-Campos, M., Giraldo, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430037/ http://dx.doi.org/10.1097/01.HS9.0000849020.51692.b3

Ejemplares similares

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Suicidal attempt with eliglustat overdose
por: Nadler, Johannes, et al.
Publicado: (2022)

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
por: Kamath, Ravi S., et al.
Publicado: (2014)

Santiago de Chile, 1541-1991 : historia de una sociedad urbana /
por: De Ramón, Armando 1927-2004
Publicado: (1992)

Profile of eliglustat tartrate in the management of Gaucher disease
por: Sechi, Annalisa, et al.
Publicado: (2016)

The population history of England 1541–1871. A reconstruction
por: Mathias, Peter
Publicado: (1984)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Publicado: (2016)

Historia sociodemográfica de Santiago de Guatemala, 1541-1773 /
por: Lutz, Christopher
Publicado: (1984)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
por: Bennett, Lunawati L, et al.
Publicado: (2015)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
por: Wang, Qiong, et al.
Publicado: (2019)

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials
por: Lukina, Elena, et al.
Publicado: (2020)

1541. Prevalence of Asymptomatic Sexually Transmitted Infections (STIs) in a Philadelphia Ryan White HIV population
por: Stuccio, Sarah, et al.
Publicado: (2020)

Charity and power in early modern Italy: benefactors and their motives in Turin, 1541–1789
por: Mackenney, Richard
Publicado: (1996)

1541. HIV Risk Assessment in Boston Community Health Center Dental Clinics
por: Konstandt, Daryl, et al.
Publicado: (2023)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum]
Publicado: (2015)

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
por: Peterschmitt, M. Judith, et al.
Publicado: (2019)

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1
por: Vu, Lucie, et al.
Publicado: (2020)

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
por: Lukina, Elena, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

1541. Infectious Complications in Adult Patients with Hemophagocytic Lymphohistiocytosis: A Single-Center Experience
por: Nelson, Joanna, et al.
Publicado: (2018)

1541. A Novel and Fast Liquid Chromatography Method for Determination of Fluoroquinolones in Human Plasma
por: Yildirim, Sercan, et al.
Publicado: (2019)

Theophrastus Bombastus Von Hohenheim (Paracelsus) (1493–1541): The eminent physician and pioneer of toxicology
por: Michaleas, Spyros N., et al.
Publicado: (2021)

International Brazilian Journal of Urology reached the biggest Impact Factor of its history - 1,541
Publicado: (2021)

P1541: CONVALESCENCE NEW LIQUID COOLING THERAPY ON PREVENTION AND TREATMENT OF CHEMOTHERAPEUTIC ORAL MUCOSITIS
por: He, Yang, et al.
Publicado: (2023)

Total Synthesis of Eliglustat via Diastereoselective Amination of Chiral para-Methoxycinnamyl Benzyl Ether
por: Kong, Younggyu, et al.
Publicado: (2022)

Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States
por: Nalysnyk, Luba, et al.
Publicado: (2018)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
por: Komada, Naoto, et al.
Publicado: (2021)

Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat
por: Harai, Nozomi, et al.
Publicado: (2023)

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
por: Mistry, Pramod K., et al.
Publicado: (2021)

Research at GANIL: a compilation 1996-1997
por: Balanzat, E, et al.
Publicado: (1998)

A Transcontinental Challenge — A Test of DNA Barcode Performance for 1,541 Species of Canadian Noctuoidea (Lepidoptera)
por: Zahiri, Reza, et al.
Publicado: (2014)

1541 The Changing Molecular Epidemiology of HIV in the Philippines: Major Shift from Subtype B to CRF01_AE
por: Schwem, Brian, et al.
Publicado: (2014)

Anmerkung zu BVerfG, Beschl. v. 16.12.2021 – 1 BvR 1541/20
por: Huster, Stefan
Publicado: (2022)

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat
por: Abrams, Ruth, et al.
Publicado: (2020)

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review
por: Nabizadeh, Azita, et al.
Publicado: (2018)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
por: Lee, Ni-Chung, et al.
Publicado: (2022)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8e63d384oo35aipcae87tmjr9h